All kinds of Fund of DSE and CSE are going under pressure having notice from the two stock exchange that any Fund does not have facility to declare dividend for their share holders. In a press notice DSE and CSE said that there is no scope to declare any dividend by any Fund Company as there is no such evidence in international market. They also said that as all Funds are not industry based or product based Company, hence they do not have ability to declare dividend. Both Stocks of BD hawk the investors to invest safely finding the inner strength of the company.
Analyst Shah DOWNGRADED all kinds of Funds of BD Socks. He mainly kept fucas on Aims 1st and all ICB Funds for around a month. He said in his research note that investors should stand on a ground of safe floor keeping aloof from Aims 1st.
Monday, June 30, 2008
MRK lost agreement of 200 with SGP
30 June Merck & Co and Schering-Plough have decided to withdraw a New Drug Application for a combination tablet of the firms’ big-selling Claritin and Singulair, and are terminating their eight-year respiratory joint venture.
It is not an overly-surprising decision, coming as it does a couple of months after the two companies received a not-approvable letter from the FDA for a proposed fixed combination of SGP’s Claritin (loratadine) and Merck’s Singulair (montelukast) for the treatment of allergic rhinitis symptoms. The respiratory deal was set up in 2000 specifically to develop and sell the combination pill.
As a result SGP expects to receive $105 million from Merck, to be recognised over the remaining three quarters of 2008. The companies also noted that the actions had no impact on their cholesterol joint venture, through which they market the controversial drug Vytorin, a combination of Zetia (ezetimibe) and Zocor.
And in other news that seems good that Merck announced the results of its new study in which its investigational candidate, odanacatib, reduced measures of bone turnover in women with breast cancer that has spread to the bones which were presented at the International Meeting on Cancer Induced Bone Disease.
Analyst Shah downgraded the stock and made his target price $ 34. He suggest the investor to go SHORT from around $ 38.
It is not an overly-surprising decision, coming as it does a couple of months after the two companies received a not-approvable letter from the FDA for a proposed fixed combination of SGP’s Claritin (loratadine) and Merck’s Singulair (montelukast) for the treatment of allergic rhinitis symptoms. The respiratory deal was set up in 2000 specifically to develop and sell the combination pill.
As a result SGP expects to receive $105 million from Merck, to be recognised over the remaining three quarters of 2008. The companies also noted that the actions had no impact on their cholesterol joint venture, through which they market the controversial drug Vytorin, a combination of Zetia (ezetimibe) and Zocor.
And in other news that seems good that Merck announced the results of its new study in which its investigational candidate, odanacatib, reduced measures of bone turnover in women with breast cancer that has spread to the bones which were presented at the International Meeting on Cancer Induced Bone Disease.
Analyst Shah downgraded the stock and made his target price $ 34. He suggest the investor to go SHORT from around $ 38.
Thursday, June 26, 2008
A Recent view on Helthcare Sectors
A JPMorgan analyst placed "Buy" ratings on shares of Merck & Co. and Schering-Plough Corp. Wednesday, but voiced cautions on the pharmaceutical sector and on shares of other major drug makers. The top issues facing drug makers include a more cautious Food and Drug Administration and a wave of patent expirations on blockbuster drugs over the next few years. Merck is in top pick, as shares should rise as the company builds sales of its diabetes treatment Januvia and its human papillomavirus vaccine Gardasil, along with restructuring efforts that are lowering its costs. Schering-Plough's buyout of Organon Biosciences by $14.5 billion deal that closed in November should allow the company to significantly improve its profit margins. These two companies are also the most protected from a new "patent cliff" under a period where a large number of valuable drugs go off-patent between 2010 and 2012,
JPMorgan gave "Neutral" ratings to Bristol-Myers Squibb Co. and Pfizer Inc. because some of their most important drugs will lose patent protection over the next few years. Wyeth has little to offer beyond its Alzheimer's drug candidate bapineuzumab, and Eli Lilly & Co.'s pipeline consists mostly of early-stage drugs
The sector has also been hit by concerns about the effectiveness of drugs already on the market wrote Shah in his research note.
JPMorgan gave "Neutral" ratings to Bristol-Myers Squibb Co. and Pfizer Inc. because some of their most important drugs will lose patent protection over the next few years. Wyeth has little to offer beyond its Alzheimer's drug candidate bapineuzumab, and Eli Lilly & Co.'s pipeline consists mostly of early-stage drugs
The sector has also been hit by concerns about the effectiveness of drugs already on the market wrote Shah in his research note.
Subscribe to:
Posts (Atom)
